Daily Stock Analysis, ADVM, Adverum Biotechnologies Inc, priceseries

Adverum Biotechnologies Inc. Daily Stock Analysis
Stock Information
Open
2.85
Close
2.75
High
2.95
Low
2.75
Previous Close
2.85
Daily Price Gain
-0.10
YTD High
3.35
YTD High Date
Jan 5, 2017
YTD Low
2.50
YTD Low Date
Apr 19, 2017
YTD Price Change
-0.20
YTD Gain
-6.78%
52 Week High
4.86
52 Week High Date
Aug 4, 2016
52 Week Low
2.50
52 Week Low Date
Apr 19, 2017
52 Week Price Change
-0.48
52 Week Gain
-14.86%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 9. 2015
37.08
Mar 25. 2015
40.80
12 Trading Days
10.04%
Link
LONG
Oct 27. 2015
8.03
Nov 10. 2015
8.53
10 Trading Days
6.19%
Link
LONG
Nov 18. 2015
8.43
Dec 3. 2015
9.26
10 Trading Days
9.83%
Link
LONG
Apr 15. 2016
5.36
Apr 27. 2016
5.83
8 Trading Days
8.80%
Link
LONG
Aug 2. 2016
3.54
Aug 17. 2016
4.27
11 Trading Days
20.73%
Link
Company Information
Stock Symbol
ADVM
Exchange
NasdaqGM
Company URL
http://www.adverumbio.com
Company Phone
650-272-6269
CEO
Amber Salzman
Headquarters
California
Business Address
1035 O'BRIEN DRIVE, MENLO PARK, CA 94025
Sector
-
Industry Category
-
Industry Group
-
CIK
0001501756
About

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Description

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.